Glycosaminoglycans and sulphated polyanions attenuate the neurotoxic effects of beta-amyloid.
Sadler
I I
II
Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Harlow, Essex, UK.
Hawtin
S R
SR
Tailor
V
V
Shearman
M S
MS
Pollack
S J
SJ
D016229:Amyloid beta-Peptides / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000633:toxicity*; D000818:Animals; D002470:Cell Survival / Q000187:drug effects*; D004396:Coloring Agents; D003224:Congo Red / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006025:Glycosaminoglycans / Q000494:pharmacology*; D009498:Neurotoxins / Q000633:toxicity*; D016716:PC12 Cells; D010446:Peptide Fragments / Q000494:pharmacology; D051381:Rats; D013778:Tetrazolium Salts; D013844:Thiazoles
D016229:Amyloid beta-Peptides; D004396:Coloring Agents; D006025:Glycosaminoglycans; D009498:Neurotoxins; D010446:Peptide Fragments; D013778:Tetrazolium Salts; D013844:Thiazoles; C078592:amyloid beta-protein (1-40); C074636:amyloid beta-protein (25-35); D003224:Congo Red; C022616:thiazolyl blue